

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

[illegible][illegible]

12/05/2006

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
Application Number	10/677,956				
Filing Date	10/01/2003				
First Named Inventor	Suzanne Zebedee				
Art Unit	1648				
Examiner Name	Zachariah Lucas				
Attorney Docket Number	323-100US D				
Sheet	2	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ZL		HOUGHTON, ET AL., Int. K. Prot. Res., 16:311-320 (1980)	
		CHOO, ET AL., Science, 244:359-362 (1989)	
		ALTER, ET. AL., NEJM, 321:1538-39 (1989)	
		KUO, ET AL., Science, 244:362-364 (1989)	
		MEYERS, ET AL., Virol., 171:555-567 (1989)	
		KATO, ET AL., PNAS, 87:9524-9528 (1990)	
		GRAY, ET AL., Lancet, 335:609-610 (1990)	
		MCFARLANE, ET AL., Lancet, 335:754-757 (1990)	
		WEINER, ET AL., Lancet, 335:1-3 (1990)	
		MILLER, ET AL., PNAS, 87:2057-2061 (1990)	
ZL		TAKEUCHI, ET AL., Nucl. Acids Res., 18:4626 (1990)	

Examiner Signature	/Zachariah Lucas/	Date Considered	12/05/2006
---------------------------	-------------------	------------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/677,956
		Filing Date	10/01/2003
		First Named Inventor	Suzanne Zebedee
		Art Unit	1648
		Examiner Name	Zachariah Lucas
		Attorney Docket Number	323-100US D
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ZL		PRINCE, ET AL., "Long-Incubation of Post-Transfusion Hepatitis Without Serological Evidence of Exposure to Hepatitis-B Virus", The Lancet, 2:241 (1974)	
		PRINCE, ET AL., "Posttransfusion Viral Hepatitis caused by an Agent or Agents Other than Hepatitis B Virus or Hepatitis A Virus. Impact on Efficiency of Present Screening Methods", Transmissible Disease & Blood Transfusion, Tibor et al. eds., Grune & Stratton, Inc., pp. 129-140 (1975)	
		PRINCE, ET AL., "Non-A/Non-B Hepatitis: Identification of a Virus-specific Antigen and Antibody. A Preliminary Report", Viral Hepatitis, Vyas et al. eds., Franklin Institute Press, Philadelphia, PA, pp. 633-640.	
		PRINCE, ET AL., "Non-A, Non-B Hepatitis: Reproduction Of Disease In Chimpanzees And Identification Of Virus Specific Antigen and Antibody", Transplantation and Clinical Immunology, Vol. X, Touraine et al. eds., Excerpta Medica, Amsterdam, pp. 8-17 (1979)	
		PRINCE, A.M., "Nature of Non-A, Non-B Hepatitis Viruses", The Lancet, pp. 1181-2, May, 22, 1982	
		PRINCE, ET AL., "Use of Liver Cell Cultures in Studies on the Replication of Hepadna and Non-A, Non-B Viruses", Viral Hepatitis and Liver Disease, Grune & Stratton, pp. 459-464 (1984)	
		BROTMAN, ET AL., "Non-A, Non-B Hepatitis: Is There More Than a Single Blood-Borne Strain?", J. Infect. Diseases, Vol. 151, No. 4, pp. 618-625 (1985)	
		BRINTON, ET AL., "Sequence and Secondary Structure Analysis of the 5'-Terminal Region of Flavivirus Genome RNA", Virol., 162:290-299 (1988)	
		COLLETT, ET AL., "Molecular Cloning and Nucleotide Sequence of the Pestivirus Bovine Viral Diarrhea Virus", Virol., 165:191-199 (1988)	
		HAHN, ET AL., "Nucleotide Sequence of Dengue 2 RNA and Comparision of the Encoded Proteins with Those of Other Flaviviruses", Virol., 162:167-180 (1988)	
ZL		TAKEUCHI, ET AL., "Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis", Gene, 91:287-291 (1990)	

Examiner Signature	/Zachariah Lucas/	Date Considered	12/05/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/677,956		
		Filing Date	10/01/2003		
		First Named Inventor	Suzanne Zebedee		
		Art Unit	1648		
		Examiner Name	Zachariah Lucas		
Sheet	4	of	4	Attorney Docket Number	323-100US D

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ZL		SUTCLIFFE, ET AL., "Antibodies That React with Predetermined Sites on Proteins", Science, Vol. 219, No. 4585, pp. 600-666 (1983)	
ZL		GERBER, ET AL., "Biology of Disease: Molecular and Cellular Pathology of Hepatitis B", Laboratory Investigation, Vol. 52, No. 6, pp. 572-590 (1985)	
ZL		SMITH, ET AL., "Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase", Gene, 67:31-40 (1988)	

Examiner Signature	/Zachariah Lucas/	Date Considered	12/05/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known	
	Application Number	10/677,956		
	Filing Date	10/01/2003		
	First Named Inventor	Suzanne Zebedee		
	Art Unit	1648		
	Examiner Name	Zachariah Lucas		
	Attorney Docket Number	323-100US D		
Sheet	2	of	2	


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ZL		WILKINS, J., "Late seroconversion following HPV -77, DE5 rubella virus vaccine", Am. J. Obstet. Gynecol., Vol. 121, No. 7, pp. 998-1002 (1974)	
		ALLAIN, J. P., ET AL., "Serological Markers In Early Stages Of Human Immunodeficiency Virus Infection In Haemophiliacs", The Lancet, pp. 1233-1236 (11/29/1986)	
		FARZADEGAN, H., ET AL., "Performance of Serological Assays for Early Detection of Human Immunodeficiency Virus Type 1 Seroconversion", J. of Clin. Microbio., Vol. 27, No. 8, pp. 1882-1884 (1989)	
		ALTER, H. J., ET AL., "Detection Of Antibody To Hepatitis C Virus In Prospectively Followed Transfusion Recipients With Acute And Chronic Non-A, Non-B Hepatitis", New. Eng. J. of Med., Vol. 321, No. 22, pp. 1494-1500 (1990)	
		CHOO, Q-L., ET AL., "Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis", Br. Med. Bull., Vol. 46, No. 2, pp. 423-441 (1990)	
		TAKEUCHI, K., ET AL., "The putative nucleocapsid and envelope protein genes of hepatitis C virus determined by comparison of the nucleotide sequences of two isolates derived from an experimentally infected chimpanzee and healthy human carriers", J. of Gen. Virology, Vol. 71, pp. 3027-3033 (1990)	
		OKAMOTO, H., ET AL., "The 5'-Terminal Sequence of the Hepatitis C Virus Genome", Jap. J. Exp. Med., Vol. 60, No. 3, pp. 167-177 (1990)	
		MAENO, M., ET AL., "A cDNA close closely associated with non-A, non-B hepatitis", Nucleic Acids Res., Vol. 18, No. 9, pp. 2685-2689 (1990)	
ZL		WEINER, A.J., ET AL., "Variable and Hypervariable Domains Are Found in the Regions of HCV Corresponding to the Flavivirus Envelope and NS1 Proteins and the Pestivirus Envelope Glycoproteins", Virology, Vol. 180, pp. 842-848 (1991, accepted for publication 10/18/1990)	

Examiner Signature	/Zachariah Lucas/	Date Considered	12/05/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.

323-100US D

SERIAL NO.

10/677,956

APPLICANT(S)

SUZANNE ZEBEDEE, ET AL.

FILING DATE

10/1/2003

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ZL	5,204,259	4/20/1993	HELTING ET AL.			
ZL	5,470,720	11/28/1995	HELTING ET AL.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ZL		Okamoto et al, Japan J. Exp. Med. Vol. 60, No. 4 (1990)

EXAMINER /Zachariah Lucas/	DATE CONSIDERED 12/05/2006
-------------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.